Page 12 - Air Force Material Command News Today

CytoSorb® Registered and Commercially Available in Singapore CytoSorbents announces immediate commercial availability of CytoSorb in Singapore through distributor Humedical News provided by Share this article MONMOUTH JUNCTION, N.J., May 25, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in the intensive care unit (ICU) and cardiac surgery, announces that the Singapo...

WRIGHT-PATTERSON AIR FORCE BASE, Ohio (AFRL) – A senior technical advisor with the Air Force Research Laboratory’s Aerospace Systems Directorate inspired her daughter to embark on a military career full of adventure and multicultural experiences.Lisa,

    Col. Louis Ruscetta, as an Air Force brat, has spent much of his life at flightlines around the world.  Today, he serves as Senior Materiel Leader for the B-52 program office and leads a team that is working to ensure the B-52 is available when the nation calls.    “Theres such a special culture in the BUFF [Big Ugly Fat Fellow] that youre part of something thats unique and historic,” Ruscetta said during an episode of AFLCMC’s Leadership Log podcast.  “Theres just this love o...

/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly...

Share this article Share this article MONMOUTH JUNCTION, N.J., May 11, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® and other blood purification technologies to treat deadly conditions in critically-ill and cardiac surgery patients around the world, announced the U.S Army Medical Research and Development Command has awarded CytoSorbents a Defense Health Agency (DHA) Sequential Phase II Small Business Innovation Research (S...

To embed, copy and paste the code into your website or blog: In a time of uncertain federal budgets and an increasingly crowded marketplace, contractors of all sizes are on the lookout for ways to enhance their chances of winning federal business opportunities. Step one in this process is, of course, the identification of the government’s needs—which are typically codified in requests for proposals or quotations. Step two ( i.e., the “pursuit” phase) involves the preparation of an offer...

By 1st Lt Savanah Bray, 53d Wing / Published April 29, 2021 An F-15EX Eagle II from the 85th Test and Evaluation Squadron, 53rd Wing, takes flight for the first time out of Eglin Air Force Base, Fla., April 26, 2021, prior to departure for Northern Edge 2021. The F-15EX brings next-generation combat technology to a highly successful fighter airframe that is capable of projecting power across multiple domains for the Joint Force. (U.S Air Force photo by 1st Lt Savanah Bray) F-35...

5 More than 25 aircraft, and hundreds of Airmen, from across the 53rd Wing are headed to Alaska in support of Northern Edge 21, INDOPACOM’s premier bi-annual exercise designed to increase joint combat effectiveness in all spectrums of warfare, May 3-14, 2021. Though Northern Edge provides an elite training venue for the Combat Air Forces, for the 53rd Wing, Northern Edge is an opportunity to test software, hardware and tactics in a unique and complex environment for fighter, ...

CytoSorbents to Report Q1 2021 Operating and Financial Results News provided by Share this article Share this article MONMOUTH JUNCTION, N.J., April 27, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q1 2021 financial results after the market close on Tuesday, May 4, 2021 at 4...

Ticagrelor ( STAR-T) randomized, controlled trial.  Based on this conditional approval, study initiation activities, including clinical trial agreement negotiations and institutional review board (IRB) submissions, can now commence, putting the study ahead of the Companys internal schedule.  The Company has already identified and pre-screened many high-quality U.S. clinical centers that have indicated strong interest to participate in the STAR-T trial.  The Company believes conditions for f...